Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTP (ID: DTFI42L)

• DTP Name: Multidrug resistance-associated protein 2 (ABCC2) DTP Info
• Gene Name: MRP2

Molecule-Related Drug & Molecule List

74 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[1]
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[2]
Adefovir	DMM278X	N. A.	N. A.	Approved	[3]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[6]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[7]
Cefodizime	DMORSGU	N. A.	N. A.	Approved	[4]
Ceftriaxone	DMCEW64	Acute gonococcal cervicitis		Approved	[4]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[8]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[9]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[10]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[11]
Dehydroepiandrosterone sulfate	DM4Q80H	N. A.	N. A.	Approved	[12]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[13]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[14]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[15]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[16]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[17]
Estrone sulfate	DMVBIZL	Atrophic vaginitis	GA30.2	Approved	[18]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[19]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[20]
FLUORESCEIN	DMQTFAO	Ocular disease	1F00.1Z	Approved	[21]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[22]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[23]
Gadobenate Dimeglumine	DM4VAOG	Schizophrenia	6A20	Approved	[24]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[25]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[26]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[27]
Grepafloxacin	DMGLX0T	Chronic bronchitis	CA20.1	Approved	[28]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[29]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[30]
Leucovorin	DMUAZWG	Colon adenocarcinoma		Approved	[31]
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[32]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[33]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[34]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[4]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[35]
Mycophenolic acid	DMRBMAU	Crohn disease	DD70	Approved	[36]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[37]
Octreotide	DMHIDCJ	Acromegaly	5A60.0	Approved	[38]
Olamufloxacin	DMQ4PKA	N. A.	N. A.	Approved	[39]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[40]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[41]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[42]
Pemetrexed	DMMX2E6	Central nervous system lymphoma	2B33.5	Approved	[39]
Pemirolast	DML97WV	Allergic conjunctivitis	9A60.02	Approved	[39]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[43]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[44]
Pitavastatin	DMJH792	Hypercholesterolaemia	5C80.0	Approved	[45]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[4]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[46]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[47]
Raltitrexed	DMT9K8G	Rectal adenocarcinoma	2B92	Approved	[48]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[49]
Rifampin	DMA8J1G	Tuberculosis	1B10-1B1Z	Approved	[50]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[29]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[51]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[52]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[53]
Succimer	DME81IY	Metal intoxication	NE60	Approved	[54]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[55]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[56]
Technetium (99MTC) mebrofenin	DMUEWM3	N. A.	N. A.	Approved	[4]
Telithromycin	DMZ4P3A	Bacterial infection	1A00-1C4Z	Approved	[15]
Temocaprilate	DMNX2QI	N. A.	N. A.	Approved	[4]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[3]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[57]
Vasopressin	DMQ2FPC	Diabetes insipidus	5A61.5	Approved	[58]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[59]
Vincristine	DMINOX3	Acute lymphoblastic leukaemia	2A85	Approved	[4]
VRX496	DMIO4V5	Acquired immune deficiency syndrome	1C62.3	Approved	[4]

9 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
GLYCYRRHIZIN	DM8M2N3	Influenza virus infection	1E30-1E32	Phase 3	[39]
BQ-123	DM0MO8I	Pulmonary arterial hypertension	BB01.0	Phase 2	[39]
CKD602	DMW9F1G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[39]
Glutathione-S-S-glutathione	DMJ85FS	N. A.	N. A.	Phase 2	[60]
LE-SN38	DMW50NF	Colorectal cancer	2B91.Z	Phase 2	[61]
PEITC	DMOMN31	Prostate cancer	2C82.0	Phase 2	[62]
EPICATECHIN	DMN0EMP	Duchenne dystrophy	8C70	Phase 1/2	[63]
Sodium taurocholate	DM3GO0J	Type-2 diabetes	5A11	Phase 1/2	[64]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenolphthalein	DM5SICT	Constipation	DD91.1	Withdrawn from market	[65]
Rhodamine-123	DMQAK6T	Prostate cancer	2C82.0	Discontinued in Phase 1	[66]

3 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-Zearalenol	DMQMAWK	N. A.	N. A.	Preclinical	[67]
Scutellarin	DMJT1E5	N. A.	N. A.	Preclinical	[68]
Taxifolin	DMQJSF9	N. A.	N. A.	Preclinical	[69]

11 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMINOHIPPURIC ACID	DMUN54G	Discovery agent	N.A.	Investigative	[70]
bilirubin	DMI0V4O	Discovery agent	N.A.	Investigative	[71]
CCK-8	DMN0J4W	N. A.	N. A.	Investigative	[18]
chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[39]
Genistein-7-glucoside	DMMLNTW	N. A.	N. A.	Investigative	[4]
glycocholic acid	DM0SXNM	Discovery agent	N.A.	Investigative	[72]
N5-methylfolate	DML0R9M	Discovery agent	N.A.	Investigative	[39]
Phlorizin	DMNARGO	Discovery agent	N.A.	Investigative	[4]
talinolol	DMRTD16	Discovery agent	N.A.	Investigative	[73]
tauroursodeoxycholic acid	DMFKRQE	Discovery agent	N.A.	Investigative	[74]
[3H]estradiol-17beta-glucuronide	DM3KJ45	Discovery agent	N.A.	Investigative	[75]

References

• [1] Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
• [2] Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86.
• [3] Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
• [4] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [5] MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
• [6] A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
• [7] Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
• [8] Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
• [9] Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
• [10] Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8.
• [11] Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
• [12] Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23.
• [13] Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
• [14] Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
• [15] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [16] Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
• [17] Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
• [18] Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
• [19] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [20] Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17.
• [21] Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76.
• [22] Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
• [23] Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
• [24] Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
• [25] Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010 Aug 16;395(1-2):251-9.
• [26] Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
• [27] Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007 Nov;46(5):1597-610.
• [28] Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
• [29] Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
• [30] Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
• [31] Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
• [32] Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
• [33] Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006 Oct;62(10):871-5.
• [34] Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
• [35] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [36] C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
• [37] Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
• [38] P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
• [39] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [40] Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
• [41] Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
• [42] Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
• [43] Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15.
• [44] Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
• [45] Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
• [46] Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
• [47] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9.
• [48] Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5.
• [49] Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
• [50] Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
• [51] Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
• [52] Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
• [53] Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
• [54] MRP2 involvement in renal proximal tubular elimination of methylmercury mediated by DMPS or DMSA. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):10-7.
• [55] Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
• [56] Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
• [57] Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
• [58] Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41.
• [59] Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
• [60] Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. Eur J Biochem. 1999 Oct 1;265(1):281-9.
• [61] Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.
• [62] Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol. 2005 Aug 15;70(4):640-7.
• [63] Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res. 2001 Oct;18(10):1420-5.
• [64] Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
• [65] Biliary excretion of phenolphthalein sulfate in rats. Pharmacology. 2003 Aug;68(4):177-82.
• [66] Characterization of rhodamine-123, calcein and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur J Pharm Sci. 2011 Aug 17;43(5):359-69.
• [67] ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol Lett. 2009 Oct 28;190(2):215-23.
• [68] Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
• [69] Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp. Int J Pharm. 2009 Aug 13;378(1-2):1-8.
• [70] ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
• [71] Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90.
• [72] Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003 Jun 27;278(26):23529-37.
• [73] FDA Drug Development and Drug Interactions
• [74] Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther. 2007 Feb;320(2):893-9.
• [75] Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929-37.